Pipeline
ENABLING BROAD APPLICATIONS FOR RNA TREATMENTS
Replicate is advancing a robust pipeline of srRNA treatments spanning several therapeutic areas. Our pipeline achieves initial clinical proof of concept in infectious disease, demonstrating a best-in-class technology, advances a first-in-class oncology candidate to IND, and demonstrates the potential of the technology with two candidate selections in major therapeutic areas with clear preclinical inflection points.
Program
Indication
Mechanism
of action
of action
Discovery
Preclinical
Phase 1
Partner
Vaccines
(LATAM rights)
RBI-4000
Rabies vaccine
Viral glycoprotein
PHASE 1 – COMPLETE
RBI-6000
RSV/hMPV/PIV
Multiple antigens
Preclinical
Wholly Owned
RBI-5000
Infectious mononucleosis
Multiple antigens of Epstein Barr virus
Preclinical
Wholly Owned
Therapeutics
RBI-8000
Chronic refractory gout; expansion on proof of concept
Pan inflammasome inhibitor
(IL-1/IL-18 inhibitor)
(IL-1/IL-18 inhibitor)
Discovery
Wholly Owned
RBI-X000
Obesity,
Diabetes, other cardiometabolic
Diabetes, other cardiometabolic
Undisclosed
Discovery
Precision Immunotherapy
RBI-1000
ER+ breast cancer
Endocrine therapy resistance
Preclinical
Clinical trial information
Replicate is currently studying RBI-4000 in a Phase 1 clinical trial to evaluate clinical proof of concept, safety, and tolerability in humans. To find out more about the trial and eligibility, visit: